What Kelonia's journey to exit could mean for cell & gene therapies | Bryan Roberts (Venrock)
Bryan Roberts from Venrock discusses Eli Lilly's acquisition of Kelonia, a gene therapy company. He covers the investment thesis, challenges of the biotech financing freeze, and the current landscape for cell and gene therapies, including pricing and infrastructure. Kelonia…